Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Blank, Antje, Fürle, Kristin, Jäschke, Anja, Mikus, Gerd, Lehmann, Monika, Hüsing, Johannes, Heiss, Kirsten, Giese, Thomas, Carter, Darrick, Böhnlein, Ernst, Lanzer, Michael, Haefeli, Walter E., Bujard, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994672/
https://www.ncbi.nlm.nih.gov/pubmed/32025341
http://dx.doi.org/10.1038/s41541-020-0160-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994672/
https://www.ncbi.nlm.nih.gov/pubmed/32025341
http://dx.doi.org/10.1038/s41541-020-0160-2

Ejemplares similares